Analysis of Medication Patterns in Traditional Chinese Medicine for the Prevention and Treatment of COVID-19 in the Elderly Based on Data Mining

Abstract

Abstract: Objective：To systematically analyze traditional Chinese medicine (TCM) prescription pattern of COVID-19 and investigate the patterns of TCM used in the elderly. Methods：To organize the latest TCM prevention and treatment protocols for COVID-19 by the National， Provincial and Municipal Health Commissions and administrations before January 10， 2023 (inclusive)， and develop a data extraction table. The ancient and modern medical case cloud platform (V2. 3. 5) was used to analyze the composition of Chinese medicine drugs used in the elderly. Results： Thirty protocols for were included. A total of 79 herbal prescriptions were recommended for the elderly， and no prescription for recovery. The main treatment methods were beneficial to qi and yang， lung and intestine together， and clearing heat and phlegm. The comparison between the prescriptions for prevention and the prescriptions for treatment showed that the drugs mainly included Fangfeng， Huangqi and Atractylodes， which were slightly warm in nature and sweet in taste， and were attributed to the lung and spleen meridians. The drugs prescribed for treatment mainly included Jinyinhua， licorice， rhizome and bitter almond， which were mainly cold in nature and sweet， bitter， and pungent in taste， and were mostly attributed to the lung， stomach， spleen and heart meridians. The correlation analysis between underlying diseases and traditional Chinese medicine suggested common symptoms and drugs.Conclusion：The principle of prevention is to dispel wind， benefit qi and consolidate the surface， and tonify qi and strengthen the spleen， while the treatment is mostly based on promoting the lung and dispersing evil， clearing heat and dispelling dampness. The treatment should be based on clinical symptoms， identify different types of symptoms， and follow the basic principles and ideas of Chinese medicine treating based on pattern differentiation， adapting to the individual， and supporting the righteous and eliminating the evil. Elderly patients with underlying diseases can be treated with additional prescriptions according to the evidence. It is recommended to increase recovery prescription to effectively improve the health of the elderly.

Key words: font-size:medium, ">COVID-19； Elderly；Traditional Chinese medicine；Data mining；Medication patterns

CLC Number:

MA Yi-xin, SUN Xin, WU Xiao-dan, MENG Yan-yan, FEI Yu-tong, RONG Hong-guo, . Analysis of Medication Patterns in Traditional Chinese Medicine for the Prevention and Treatment of COVID-19 in the Elderly Based on Data Mining[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(2): 107-114.

References

[1]周永学. 新型冠状病毒感染肺炎中医病因病机与治法探讨[J]. 陕西中医药大学学报， 2020， 43(5)： 28-32.
     [2]张春，林婷，郭利涛，等. 新型冠状病毒肺炎老年患者的临床特点及转归分析[J]. 西安交通大学学报(医学版)， 2021， 42(6)： 9159-9122.
     [3]王维，王兰，姜尚上，等. 基于古今医案云平台的中医药防治新型冠状病毒肺炎用药规律研究[J]. 北京中医药， 2020， 39(8)： 800-805，901.
     [4]（明）吴又可著. 温疫论[M]. 北京：中国医药科技出版社， 2019.
     [5]张天宇，吴振起，任园园，等. 古代肺系疫病处方用药规律探析[J]. 中国中医药信息杂志， 2021， 28(11)： 15-20.
     [6]萨日娜，张冰，邓娟，等. 老年人新型冠状病毒肺炎中药防治的合理用药策略[J]. 中国医院药学杂志， 2020， 40(8)： 852-856.
     [7]周鸿飞，李丹点校. 灵枢经[M]. 郑州：河南科学技术出版社， 2017.
     [8]徐旭，张莹，李新，等. 各地区中医药预防新型冠状病毒肺炎(COVID-19)方案分析[J]. 中草药， 2020， 51(4)： 866-872.
     [9]包兆含，张文，邬鑫鑫，等. “截断扭转-扶正固本”法治疗疫病思想对新型冠状病毒肺炎救治的启示[J]. 中国中医急症， 2020， 29(8)： 1320-1322.
     [10]王俊蕾，张成博，罗光芝，等. 从“肺肾相生”探究老年人新型冠状病毒肺炎防治及预后[J]. 山东中医药大学学报， 2021， 45(6)： 766-770.
     [11]刘清泉，齐文升，陈腾飞，等. 北京市新型冠状病毒肺炎重型、危重型中医诊疗专家共识[J]. 北京中医药： 2023，42（1）：47-50.
     [12]赵新，张林旭，路雪婧. 基于数据挖掘预防新型冠状病毒肺炎中医方药初探[J]. 中草药， 2020， 51(5)： 1147-1152.
     [13]（清）吴瑭著. 宋咏梅，臧守虎，张永臣点校. 温病条辨[M]. 北京：中国中医药出版社， 2006.
     [14]高学敏主编. 中药学[M]. 北京：中国中医药出版社， 2002.
     [15]杨洁，庞震苗，刘琼，等. 基于数据挖掘的新型冠状病毒肺炎中医防治方药分析[J]. 中医临床研究， 2021， 13(36)： 41-45.
     [16]马宇博，贾婷婷，张瑞芬，等. 新冠肺炎中医药诊疗思考[J]. 中华中医药学刊： 1-12.
     [17]牛翊霖，张纯，曹雯煜，等. 年龄因素对新型冠状病毒易感性的影响[J]. 新发传染病电子杂志， 2022， 7(2)： 19-24.
     [18]胡耀木，吴悠，张秋娥，等. 基于数据挖掘与“内热伤阴耗气”探讨糖尿病合并新型冠状病毒肺炎的中药治疗[J]. 世界科学技术-中医药现代化， 2021， 23(3)： 850-855.
     [19]李方怡，陈永华，徐寒松，等. 徐寒松教授运用黄芪治疗消渴病临证经验[J]. 中国民族民间医药， 2019， 28(16)： 75-77.
     [20]马晶晶，杨辰华，张社峰，等. “风药开玄”在糖尿病治疗中的应用[J]. 中华中医药杂志， 2021， 36(12)： 7199-7202.
     [21]马艳春，段莹，胡建辉，等. 黄芪治疗糖尿病及其并发症研究进展[J]. 中医药学报， 2022， 50(6)： 103-107.
     [22]王晓波，支文兰，赵福来，等. 浅谈新型冠状病毒肺炎合并基础病的中医药防治策略[J]. 世界科学技术-中医药现代化， 2021， 23(2)： 344-350.
     [23]任红. 研究中药天麻的鉴定方法和药理作用[J]. 中西医结合心血管病电子杂志， 2018， 6(18)： 165-166.
     [24]崔洁，于远望. 生脉散防治心血管疾病的研究进展[J]. 现代中医药， 2018， 38(3)： 78-81.
     [25]符爽，邢大林，张庆镐，等. 近10年红景天对心血管疾病的药理作用[J]. 解剖科学进展， 2021， 27(6)： 759-762，768.
     [26]景选龙，李龙山，王茂锦，等. 仲景方应用姜辛味探析[J]. 亚太传统医药， 2016， 12(22)： 73-74.

Analysis of Medication Patterns in Traditional Chinese Medicine for the Prevention and Treatment of COVID-19 in the Elderly Based on Data Mining

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	DAI Qi, LI Kang-xi, YE Qiao-bo, WEN Yong-sheng, XU Li, LI Ji. Reaserch Progress on Chemical Constituents，Pharmacological Effects and Toxicology of Bombyx Batryticatus [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 402-408.
[2]	ZHAO Lei, YANG Ming, WANG Hao, MA yu, MA Jin-gan, JIANG Da-cheng, WANG Lu-hong, ZAN Ke. Investigation and Risk Assessment of Mycotoxins in Seabuckthorn during Different Harvesting Periods and Drying Processes [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 377-383.
[3]	HONG Shu-hua, LIN Qi-shan, CHAI Jiang-hong, PAN Hong-ju. Study on the Determination of Zopiclone Related Substances and the Influence of Correction Factor [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 384-388.
[4]	LI Yue-chen, CUI Shao-jing, ZHAO Yue-ran. Determination of Aflatoxins in Huoxuezhitong Capsules by High Performance Liquid Chromatography Coupled with Post-column Photochemical Derivatization [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 390-395.
[5]	TIAN Jie, HAO Ai-yu, LU Lin, ZOU Pian, DONG Bin. Effect of Several Drug Compatibility on Sub-visible Particles in Infusions with Common Plastic Packagings [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 396-401.
[6]	YANG Yan-qing, CHEN Chun-mei, CHEN Wei, Wu Rui, WANG Xue-chang, DUAN Lian. Rapid Health Technology Evaluation of Sintilimab as First-line Treatment for Advanced Non-small Cell Lung Cancer [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 409-415.
[7]	JIANG Yi-Fan, CHEN Li-ping, ZHANG Ruo-yu, WU Pei-hao, QIU Jia-min, XUAN Jian-wei, BI Hui-chang. Construction of Clinical Comprehensive Value Evaluation System for Acid-inhibiting Drugs [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 416-421.
[8]	HUA Min-fan, SONG Cang-sang, LI Xing-de, LU Wei, MAO Pan-pan, WANG Guo-hui. Medication Adherence Forecast Model Research Progress in Clinical Application [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 422-425.
[9]	HUANG Bo, CAO Xiao-ming. Safety Analysis of Isotonic and Hypotonic Contrast Media for Coronary Angiography in Elderly Patients with Renal Impairment [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 426-429.
[10]	ZHANG Wen, YANG Wei-bing. Effects of Vitamin D Combined with Etocoxib on Rehabilitation，Bone Metabolism and Inflammation in Elderly Patients after Knee Replacement [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 430-434.
[11]	TIAN Jin-ya, DUAN Xiao-kai, FAN Shi-zhen. Effects of Budesonide combined with Ipratropium Bromide Solution on Lung Function， Blood Gas Analysis and Th1/Th2 Cytokines with Chronic Bronchitis [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 435-438.
[12]	ZHANG He-feng, LIANG Yu, LIU Ying, ZOU Ling-long, . Introduction of Bioanalytical Strategies and Methodologies for Genetically Modified Cell Therapy Products [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 369-376.
[13]	ZHANG He-feng, LIANG Yu, LIU Ying, ZOU Ling-long, . Bioanalysis of Gene Therapy Products： Method Development Strategy [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 361-368.
[14]	ZHANG Yu, LI Yu-man, XIA Xu-dong. Analysis of Suspected ADR Monitoring Data of Ginkgo Injection Preparations [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(5): 439-444.
[15]	YAO Qing, LIU Ying, WANG Xiao-fang, GAO Ning, WANG Miao. Excel Calculates the Population Bioequivalence of Special Preparations [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(4): 332-337.